Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

REsponse to Combined SONS and ONS in Chronic Cluster headachE

NCT05868044 · tracked via the Priya Life Science Australia tracker
Phase
Not applicable
Started
2023-05-02
Last updated
2026-04-23

Condition(s) studied

Chronic Cluster Headache

Investigational drug(s) / intervention(s)

PRIMUS

PRIMUS: PRIMUS system

Study summary

The purpose of this study is to demonstrate the safe use of the PRIMUS System in subjects with chronic cluster headache. This is a single-centre, open label, prospective, first in human study to collect initial clinical data on the PRIMUS system for the treatment of chronic cluster headache.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Main Inclusion Criteria: * Able and willing to provide informed consent * Documented chronic cluster headache for at least 1 year as per ICHD-3 criteria * Attack frequency of ≥ 4 attacks per week for ≥ 4 weeks before enrolment * Documented failure of verapamil (failure meaning ineffective, provoked unacceptable side-effects or contra-indicated) * Stable on preventive treatment for at least two weeks prior to enrolment. * Agree to refrain from starting new prophylactic cluster headache medication or other preventive treatments, from 4 weeks before entering the baseline period throughout the duration of the study * MRI available (not older than 4 years prior to study enrolment) or willing to undergo an MRI to exclude structural lesions potentially causing headache * Able and willing to complete a headache Diary Main Exclusion Criteria: * Any other chronic primary or secondary headache disorder, unless they can clearly differentiate them from cluster headache attacks based on the quality and associated symptoms * Concomitant neuromodulation, except tVNS * Previous failure to any implantable neuromodulation device for neurovascular headache * Have an existing Active Implantable Medical Device nearby the implant location (e.g. DBS, cochlear implant, …) * Metal implants in the skull (e.g. skull plates, seeds) nearby the implant * Have a pacemaker or implantable cardioverter defibrillator (ICD) * Suboccipital infiltrations with steroids and/or local anaesthetics or use of oral steroids in the past 3 months * Use of botulinum toxin injections in the past 12 weeks * Calcitonin gene-related peptide inhibitors started less than 12 weeks prior to enrolment * Women of childbearing age who are pregnant, nursing or not using contraception

Primary outcome measure(s)

  • Safety Evaluation — 4 weeks
    The primary safety assessment is the incidence of serious procedure and/or device-related adverse events in all subjects at 30 days.
  • Safety Evaluation — 12 months
    The primary safety assessment is the incidence of serious procedure and/or device-related adverse events in all subjects at the end of the study.

Trial sites (1)

FacilityCityRegionStatus
Resolve Pain Buderim Queensland

More Salvia BioElectronics trials in Australia

The RECLAIM Study. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05868044 on ClinicalTrials.gov ↗ ← All trials in Australia